Advertisement
Journal Home
Search for

Volume 5, Issue 3, Pages 271-275 (May 2009)


View previous. 10 of 14 View next.

Maximizing the Alzheimer's Disease Neuroimaging Initiative II

Maria C. CarrilloaCorresponding Author Informationemail address, Charles A. Sandersb, Russell G. Katzc

published online 13 April 2009.

Abstract 

The Alzheimer's Disease Neuroimaging Initiative is the largest public-private partnership on brain research underway at the National Institutes of Health. This 6-year study tracks cognitive and brain changes in normal subjects, those with mild cognitive impairment, and individuals with Alzheimer's disease. It was designed to provide better tools for performing effective clinical trials, and is slated to run until 2010. While data are being generated and analyzed, researchers involved in the study are developing an extension, i.e., the Alzheimer's Disease Neuroimaging Initiative II. The Foundation for the National Institutes of Health and the Alzheimer's Association convened a meeting to review the progress, evaluate future directions, and obtain the United States Food and Drug Administration's perspective on how the Alzheimer's Disease Neuroimaging Initiative could affect the drug-approval process.

a Alzheimer's Association, Chicago, IL, USA

b Foundation for the National Institutes of Health, Bethesda, MD, USA

c United States Food and Drug Administration, Washington, DC, USA

Corresponding Author InformationCorresponding author. Tel.: 312-335-5722.

 The views stated here represent those of R.G.K., and do not represent an official statement of the United States Food and Drug Administration.

PII: S1552-5260(09)00057-0

doi:10.1016/j.jalz.2009.02.005


View previous. 10 of 14 View next.